Voretigene Neparvovec-rzyl (Luxturna®)
JJ · Effective May 6, 2019
3 active Medicare policies list J3398, and 8 commercial payer policies list it. See each policy's status for the code and its official source. Listing a code is not a coverage decision: read each policy’s source for the requirements that apply.
Free account. Policy pages stay open to everyone.
JJ · Effective May 6, 2019
JM · Effective May 6, 2019
National · Effective Apr 20, 2023
8 policies from 8 payers
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
| Policy | Effective | Status of J3398 |
|---|---|---|
| Gene Therapy for Ocular Conditions | Apr 15, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Gene Therapy for Inherited Retinal Dystrophy | Aug 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Gene Therapy for Inherited Retinal Dystrophy | Aug 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Gene Therapy for Inherited Retinal Dystrophy | Aug 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Gene Therapy for Inherited Retinal Dystrophy | Aug 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Luxturna (Voretigene Neparvovec-Rzyl) | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Luxturna (Voretigene Neparvovec-Rzyl) | Oct 1, 2026 | Covered |
| Policy | Effective | Status of J3398 |
|---|---|---|
| Luxturna (Voretigene Neparvovec-Rzyl) | Oct 1, 2026 | Covered |